Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and ...

Workforce reductions are an almost annual occurrence at Atara. The biopharma waved goodbye to 20% of its staff in 2022 and then shrunk its head count by a further 25% last year as it moved its ...

THOUSAND OAKS, Calif., May 05, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

If we’re talking about the HJC RPHA 12 solely from the price point of the model tested here, I would say it’s a good value investment, that will stand the test of time, backed up by a strong ...

Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt trials of the allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate.. Atara ...

FDA places a clinical hold on Atara's EBVALLO and ATA3219 programs due to GMP compliance issues at a third-party facility. Atara to pause new participant enrollment; CAR-T programs may suspend in ...

As partners Atara Biotherapeutics and Pierre Fabre Laboratories work to grow the reach of their novel T-cell immunotherapy Ebvallo, a manufacturing-related hitch has tripped up their ambition to ...

ATARA BIOTHERAPEUTICS, INC. Condensed Consolidated Balance Sheets (Unaudited) (In thousands) September 30, December 31, 2024 2023 Assets Current ...

Atara reported on Aug. 12 a net loss of $19 million (-$3.10 a share) for the quarter ending June 30, compared with a net loss of $71.1 million (-$16.91) in the same period of the previous year.